心脏磁共振心肌挽救指数对ST段抬高型心肌梗死患者的预后价值:系统评价与Meta分析
该系统评价与Meta分析纳入18项研究(12个独立队列),评估心脏磁共振测量的心肌挽救指数(MSI)对ST段抬高型心肌梗死(STEMI)患者主要不良心血管事件(MACE)的预测价值。MSI每增加1%,MACE风险HR为0.95;MSI低于中位数与高于中位数相比,MACE的HR为5.62,但证据等级均评为弱。
要点
- MSI每增加1%,MACE风险降低,HR 0.95(95%CI 0.92–0.98),证据等级为弱。
- MSI低于中位数者MACE风险显著高于高于中位数者,HR 5.62(95%CI 3.74–8.43)。
- MSI对心肌再梗死的预后价值尚未被评估。
核心结论
- MSI在预测STEMI患者MACE方面显示出潜力,但证据等级为弱。
- 使用先进CMR技术测量的MSI对不良心血管事件的预后价值需进一步研究。
研究设计与样本
- 系统评价与Meta分析,检索PubMed、Embase、Web of Science、Cochrane Central、中国知网和万方数据。
- 纳入18项研究,覆盖12个独立队列;11个队列使用T2加权成像和T1加权晚期钆增强测量MSI,1个队列使用T2 mapping和T1 mapping。
- 采用预后研究质量评价工具评估偏倚风险,基于MSI预测MACE的HR及95%CI进行证据等级评定。
诊断标准与关键数值
- 合并MSI(95%CI)为44%(39%–49%;11项研究,2946例患者)。
- 合并MACE发生率(95%CI)为10%(7%–14%;12项研究,3011例患者中311例事件)。
- MSI每增加1%预测MACE的HR(95%CI)为0.95(0.92–0.98;5项研究,885例患者中150例事件),证据等级为弱。
- MSI低于中位数 versus 高于中位数预测MACE的HR(95%CI)为5.62(3.74–8.43;6项研究,1570例患者中166例事件),证据等级为弱。
- 合并梗死面积(95%CI)为21%(18%–23%;11项研究,2783例患者),风险区域(95%CI)为38%(34%–43%;10项研究,2022例患者)。
临床应用与阅片要点
- 7项预后研究总体显示低偏倚风险,支持MSI作为STEMI患者MACE的预测指标,可能作为风险分层工具。
- MSI每增加1%预测心源性死亡的HR(95%CI)为0.93(0.91–0.96;1项研究,202例患者中14例事件)。
- MSI每增加1%预测充血性心力衰竭的HR(95%CI)为0.96(0.93–0.99;1项研究,104例患者中11例事件)。
- MSI对心肌再梗死的预后价值尚未被测量。
局限性
- MSI预测MACE的证据等级评为弱。
- 使用先进CMR技术的MSI对不良心血管事件的预后价值需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To assess the prognostic value of myocardial salvage index (MSI) by cardiac magnetic resonance (CMR) in ST-segment elevation myocardial infarction (STEMI) patients.
METHODS: We systematically searched PubMed, Embase, Web of Science, Cochrane Central, China National Knowledge Infrastructure, and Wanfang Data to identify primary studies reporting MSI in STEMI patients with major adverse cardiovascular events (MACE) comprised of death, myocardial reinfarction, and congestive heart failure. The MSI and MACE rates were pooled. The bias of risk was assessed using the Quality In Prognosis Studies tool. The evidence level was rated based on the meta-analysis of hazard ratio (HR) and 95% confidence interval (CI) of MSI for predicting MACE.
RESULTS: Eighteen studies were included covering twelve unique cohorts. Eleven cohorts measured MSI using T2-weighted imaging and T1-weighted late gadolinium enhancement, while one cohort applied T2-mapping and T1-mapping. The pooled MSI (95% CI) was 44% (39 to 49%; 11 studies, 2946 patients), and the pooled MACE rate (95% CI) was 10% (7 to 14%; 12 studies, 311/3011 events/patients). Seven prognostic studies overall showed low risk of bias. The HR (95% CI) per 1% increase of MSI for MACE was 0.95 (0.92 to 0.98; 5 studies, 150/885 events/patients), and HR (95% CI) of MSI < median versus MSI > median for MACE was 5.62 (3.74 to 8.43; 6 studies, 166/1570 events/patients), both rated as weak evidence.
CONCLUSIONS: MSI presents potential in predicting MACE in STEMI patients. The prognostic value of MSI using advanced CMR techniques for adverse cardiovascular events needs further investigation.
CLINICAL RELEVANCE STATEMENT: Seven studies supported the MSI to serve as a predictor for MACE in STEMI patients, indicating its potential as a risk stratification tool to help manage expectations for these patients in clinical practice.
KEY POINTS: • The pooled infarct size (95% CI) and area at risk (95% CI) were 21% (18 to 23%; 11 studies, 2783 patients) and 38% (34 to 43%; 10 studies, 2022 patients), respectively. • The pooled rates (95% CI) of cardiac mortality, myocardial reinfarction, and congestive heart failure were 2% (1 to 3%; 11 studies, 86/2907 events/patients), 4% (3 to 6%; 12 studies, 127/3011 events/patients), and 3% (1 to 5%; 12 studies, 94/3011 events/patients), respectively. • The HRs (95% CI) per 1% increase of MSI for cardiac mortality and congestive heart failure were 0.93 (0.91 to 0.96; 1 study, 14/202 events/patients) and 0.96 (0.93 to 0.99; 1 study, 11/104 events/patients), respectively, but the prognostic value of MSI for myocardial re-infraction has not been measured.
引用
- Xiao, Zhong, Zhong, et al. The prognostic value of myocardial salvage index by cardiac magnetic resonance in ST-segment elevation myocardial infarction patients: a systematic review and meta-analysis. Eur Radiol. 2023. PMID: 37328640. doi:10.1007/s00330-023-09739-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。